| scholarly article | Q13442814 |
| P50 | author | Jeffrey J Adamovicz | Q55778983 |
| Kei Amemiya | Q89513808 | ||
| P2093 | author name string | James B Bliska | |
| Jr-Shiuan Lin | |||
| Stephen T Smiley | |||
| David S Perlin | |||
| Steven Park | |||
| Christopher K Cote | |||
| Jim Hill | |||
| P2860 | cites work | Interleukin-12 and the regulation of innate resistance and adaptive immunity | Q29614602 |
| Yersinia pestis--etiologic agent of plague | Q29619320 | ||
| Pathogenesis of Yersinia pestis infection in BALB/c mice: effects on host macrophages and neutrophils | Q33225645 | ||
| Absence of inflammation and pneumonia during infection with nonpigmented Yersinia pestis reveals a new role for the pgm locus in pathogenesis | Q33557963 | ||
| Immune defense against pneumonic plague | Q33584403 | ||
| Human immune response to a plague vaccine comprising recombinant F1 and V antigens | Q33788286 | ||
| The yersiniabactin transport system is critical for the pathogenesis of bubonic and pneumonic plague | Q33826085 | ||
| Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense | Q33901607 | ||
| Replication of Yersinia pestis in interferon gamma-activated macrophages requires ripA, a gene encoded in the pigmentation locus | Q33943840 | ||
| Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis | Q34034184 | ||
| Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity | Q34201893 | ||
| Risk of person-to-person transmission of pneumonic plague | Q34406504 | ||
| Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. | Q34520336 | ||
| Administration of antibody to the lung protects mice against pneumonic plague. | Q34601788 | ||
| A plasminogen-activating protease specifically controls the development of primary pneumonic plague | Q34606584 | ||
| Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. | Q35429159 | ||
| Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization | Q35557573 | ||
| Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice | Q35689282 | ||
| Development of in vitro correlate assays of immunity to infection with Yersinia pestis. | Q35783560 | ||
| Current challenges in the development of vaccines for pneumonic plague | Q36628038 | ||
| Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection | Q37066697 | ||
| Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague | Q37450884 | ||
| Predictive models and correlates of protection for testing biodefence vaccines | Q37745002 | ||
| Cell-mediated protection against pulmonary Yersinia pestis infection | Q39393406 | ||
| Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis | Q39741669 | ||
| Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection. | Q39755573 | ||
| Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague | Q40008433 | ||
| Anti-V antigen antibody protects macrophages from Yersinia pestis -induced cell death and promotes phagocytosis | Q40724134 | ||
| CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. | Q41438984 | ||
| Antibodies and cytokines independently protect against pneumonic plague. | Q41441607 | ||
| Development of a recombinant vaccine against aerosolized plague | Q41450195 | ||
| Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates | Q41451391 | ||
| Gamma interferon, tumor necrosis factor alpha, and nitric oxide synthase 2, key elements of cellular immunity, perform critical protective functions during humoral defense against lethal pulmonary Yersinia pestis infection | Q41453869 | ||
| Stat 4 but not Stat 6 mediated immune mechanisms are essential in protection against plague | Q41461188 | ||
| Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague | Q41466529 | ||
| Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains | Q41478713 | ||
| The SCID/Beige mouse as a model to investigate protection against Yersinia pestis | Q41483548 | ||
| Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine | Q41485426 | ||
| Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis | Q41488613 | ||
| Immunity in plague; a critical consideration of some recent studies. | Q41575211 | ||
| New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. | Q53432317 | ||
| Plague | Q56706594 | ||
| Plague | Q84740727 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 357-362 | |
| P577 | publication date | 2010-09-15 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague | |
| P478 | volume | 29 |
| Q92090453 | A Recombinant Attenuated Yersinia pseudotuberculosis Vaccine Delivering a Y. pestis YopENt138-LcrV Fusion Elicits Broad Protection against Plague and Yersiniosis in Mice |
| Q88964571 | A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model |
| Q35418294 | Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges |
| Q33601814 | Direct neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrV |
| Q93375305 | Escherichia coli expressed flagellin C (FliC) of Salmonella Typhi improved the protective efficacy of YopE against plague infection |
| Q33798021 | Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague |
| Q39736724 | Fibrin facilitates both innate and T cell-mediated defense against Yersinia pestis |
| Q93015468 | Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures |
| Q34633478 | HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model |
| Q34786724 | IL-17 contributes to cell-mediated defense against pulmonary Yersinia pestis infection |
| Q47293934 | Immunisation of two rodent species with new live-attenuated mutants of Yersinia pestis CO92 induces protective long-term humoral- and cell-mediated immunity against pneumonic plague |
| Q40512106 | Immunology of Yersinia pestis Infection |
| Q41384167 | Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant |
| Q36288336 | Induction of pulmonary mucosal immune responses with a protein vaccine targeted to the DEC-205/CD205 receptor |
| Q35530270 | Intranasal administration of an inactivated Yersinia pestis vaccine with interleukin-12 generates protective immunity against pneumonic plague |
| Q40485593 | Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague |
| Q41400297 | Multiple antigen peptide containing B and T cell epitopes of F1 antigen of Yersinia pestis showed enhanced Th1 immune response in murine model |
| Q33786763 | Multiple roles of Myd88 in the immune response to the plague F1-V vaccine and in protection against an aerosol challenge of Yersinia pestis CO92 in mice |
| Q28678943 | Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccines |
| Q38671761 | Novel CTL epitopes identified through a Y. pestis proteome-wide analysis in the search for vaccine candidates against plague |
| Q91826998 | Oral vaccination with live attenuated Yersinia pseudotuberculosis strains delivering a FliC180-LcrV fusion antigen confers protection against pulmonary Y. Pestis infection |
| Q38514208 | Plague vaccines: current developments and future perspectives |
| Q26823422 | Protecting against plague: towards a next-generation vaccine |
| Q92644859 | Robust Th1 cellular and humoral responses generated by the Yersinia pestis rF1-V subunit vaccine formulated to contain an agonist of the CD137 pathway do not translate into increased protection against pneumonic plague |
| Q92241416 | Shift from primary pneumonic to secondary septicemic plague by decreasing the volume of intranasal challenge with Yersinia pestis in the murine model |
| Q55361721 | Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. |
| Q90696345 | Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague |
| Q33650538 | TNFα and IFNγ but not perforin are critical for CD8 T cell-mediated protection against pulmonary Yersinia pestis infection |
| Q38589273 | The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague |
| Q35091255 | Yersinia pestis YopE contains a dominant CD8 T cell epitope that confers protection in a mouse model of pneumonic plague |
| Q35073117 | YopP-expressing variant of Y. pestis activates a potent innate immune response affording cross-protection against yersiniosis and tularemia [corrected]. |
Search more.